Analysts Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) PT at $100.20

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $100.20.

Several analysts have recently commented on LMAT shares. Roth Mkm reiterated a “buy” rating and set a $108.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Monday, December 29th. Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. Wells Fargo & Company cut their price objective on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Finally, Zacks Research cut shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in LeMaitre Vascular by 20.1% during the 4th quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock worth $51,351,000 after acquiring an additional 105,921 shares during the period. AlphaQuest LLC increased its holdings in shares of LeMaitre Vascular by 155.4% in the fourth quarter. AlphaQuest LLC now owns 27,521 shares of the medical instruments supplier’s stock valued at $2,232,000 after purchasing an additional 16,744 shares during the period. Summitry LLC raised its stake in shares of LeMaitre Vascular by 17.9% in the fourth quarter. Summitry LLC now owns 3,643 shares of the medical instruments supplier’s stock worth $295,000 after purchasing an additional 552 shares during the last quarter. MQS Management LLC acquired a new stake in shares of LeMaitre Vascular during the fourth quarter worth about $297,000. Finally, Global Retirement Partners LLC boosted its position in LeMaitre Vascular by 12,533.3% in the fourth quarter. Global Retirement Partners LLC now owns 3,411 shares of the medical instruments supplier’s stock valued at $277,000 after buying an additional 3,384 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Down 1.0%

NASDAQ:LMAT opened at $86.54 on Friday. The company’s 50-day simple moving average is $84.61 and its 200-day simple moving average is $87.79. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.45 and a current ratio of 13.58. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $105.55. The stock has a market capitalization of $1.96 billion, a P/E ratio of 37.30, a P/E/G ratio of 1.94 and a beta of 0.72.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.